报价延迟最少15分钟:2025/08/25 15:24 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
55.45 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
3.27/5.40
|
|
企业价值
3.64B
|
| 资产负债 |
|
每股账面净值
18.31
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
1.36B
|
|
每股收益
25.72
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/25 15:24 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, thecompany operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
